NexopamilAlternative Names: LU 49938
Latest Information Update: 22 Jan 2013
At a glance
- Originator Abbott GmbH & Co. KG
- Class Antiarrhythmics; Antihypertensives; Ischaemic heart disorder therapies; Phenethylamines; Small molecules
- Mechanism of Action Calcium channel antagonists; Serotonin 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Angina pectoris; Arrhythmias; Hypertension; Ischaemic heart disorders; Thrombosis